Who's prospered

Since bottoming on April 8, the BioCentury 100 Price Level Indicator has climbed nearly 13 percent. During that time, 111 issues in the BioCentury universe have gained, compared to 66 declines. However, cumulative share volume has remained in a narrow range, reflecting continued tepid demand for biotech stocks. Following is a list of stocks that